[Pneumocystis carinii pneumonia in infants with vertically acquired HIV infection in Switzerland]. 1995

C Berger, and M Albisetti, and S Fanconi, and C Rudin, and J J Cheseaux, and J Micallef, and C Kind, and D Nadal
Universitäts-Kinderklinik Zürich.

OBJECTIVE Review of incidence, clinical picture, therapy, and outcome of Pneumocystis carinii pneumonia (PCP) in infants with vertically-acquired HIV infection in Switzerland. METHODS Inquiry among members of the Swiss Pediatrics AIDS Group, review of the data base of the Swiss Neonatal HIV Study and retrospective analysis of the charts from infants with PCP. RESULTS Since 1986 PCP has been diagnosed in 10 out of 107 infants with vertically-acquired HIV infection. PCP occurred in 7 infants at the age of 3-6 months and in 3 at the age of 9-11 months. 4 infants showed symptoms related to HIV infection before developing PCP. Before the development of PCP, infection with HIV had been ascertained in 6 infants. In 2 the diagnosis was still unclear and in the 2 remaining the risk of HIV infection was not known. None of the infants was on primary prophylaxis against PCP. Signs and symptoms of PCP included cough and tachypnea (100%) as well as high fever up to 40 degrees C (90%). Transcutaneous oxygen saturation was 70-95%. Chest X-rays revealed interstitial infiltrates in 6 infants, localized infiltrates in 2 and interstitial as well as localized infiltrates in 2. The CD4+ cell count was, with one exception, < 1500/microliters, i.e. below the normal value for age. Side effects of high dose cotrimoxazole were noted in 6 patients. 5 infants required intubation and mechanical ventilation. 4 infants died due to PCP, including 3 of those who required intubation and mechanical ventilation. CONCLUSIONS PCP in infants with vertically-acquired HIV infection preferentially occurs at the age of 3 to 6 months and is often lethal, especially in patients requiring intubation. Evaluation for HIV infection should be done as early as possible in order to introduce primary PCP prophylaxis in infants at risk for this opportunistic infection.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003422 Critical Care Health care provided to a critically ill patient during a medical emergency or crisis. Intensive Care,Intensive Care, Surgical,Surgical Intensive Care,Care, Critical,Care, Intensive,Care, Surgical Intensive
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016720 Pneumocystis Infections Infections with species in the genus PNEUMOCYSTIS, a fungus causing interstitial plasma cell pneumonia (PNEUMONIA, PNEUMOCYSTIS) and other infections in humans and other MAMMALS. Immunocompromised patients, especially those with AIDS, are particularly susceptible to these infections. Extrapulmonary sites are rare but seen occasionally. P carinii Infection,P jirovecii Infection,P. carinii Infection,P. jirovecii Infection,Pneumocystis carinii Infection,Pneumocystis jirovecii Infection,Pneumocystis carinii Infections,Infection, P carinii,Infection, P jirovecii,Infection, P. carinii,Infection, P. jirovecii,Infection, Pneumocystis,Infection, Pneumocystis jirovecii,P carinii Infections,P jirovecii Infections,P. carinii Infections,P. jirovecii Infections,Pneumocystis Infection,Pneumocystis jirovecii Infections
D017088 AIDS-Related Opportunistic Infections Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus. HIV-Related Opportunistic Infections,Opportunistic Infections, AIDS-Related,Opportunistic Infections, HIV-Related,AIDS Related Opportunistic Infections,AIDS-Related Opportunistic Infection,HIV Related Opportunistic Infections,HIV-Related Opportunistic Infection,Infection, HIV-Related Opportunistic,Infections, HIV-Related Opportunistic,Opportunistic Infection, AIDS-Related,Opportunistic Infection, HIV-Related,Opportunistic Infections, AIDS Related,Opportunistic Infections, HIV Related

Related Publications

C Berger, and M Albisetti, and S Fanconi, and C Rudin, and J J Cheseaux, and J Micallef, and C Kind, and D Nadal
February 1994, BMJ (Clinical research ed.),
C Berger, and M Albisetti, and S Fanconi, and C Rudin, and J J Cheseaux, and J Micallef, and C Kind, and D Nadal
February 2001, AIDS (London, England),
C Berger, and M Albisetti, and S Fanconi, and C Rudin, and J J Cheseaux, and J Micallef, and C Kind, and D Nadal
March 1994, Archives of disease in childhood,
C Berger, and M Albisetti, and S Fanconi, and C Rudin, and J J Cheseaux, and J Micallef, and C Kind, and D Nadal
January 1994, JAMA,
C Berger, and M Albisetti, and S Fanconi, and C Rudin, and J J Cheseaux, and J Micallef, and C Kind, and D Nadal
January 1994, JAMA,
C Berger, and M Albisetti, and S Fanconi, and C Rudin, and J J Cheseaux, and J Micallef, and C Kind, and D Nadal
January 1994, JAMA,
C Berger, and M Albisetti, and S Fanconi, and C Rudin, and J J Cheseaux, and J Micallef, and C Kind, and D Nadal
July 1993, JAMA,
C Berger, and M Albisetti, and S Fanconi, and C Rudin, and J J Cheseaux, and J Micallef, and C Kind, and D Nadal
January 1998, Revista clinica espanola,
C Berger, and M Albisetti, and S Fanconi, and C Rudin, and J J Cheseaux, and J Micallef, and C Kind, and D Nadal
December 1992, Chest,
C Berger, and M Albisetti, and S Fanconi, and C Rudin, and J J Cheseaux, and J Micallef, and C Kind, and D Nadal
April 1989, European journal of pediatrics,
Copied contents to your clipboard!